Cargando…
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
In our 2020 consensus paper, we devised ten recommendations for conducting Complex Innovative Design (CID) trials to evaluate cancer drugs. Within weeks of its publication, the UK was hit by the first wave of the SARS-CoV-2 pandemic. Large CID trials were prioritised to compare the efficacy of new a...
Autores principales: | Blagden, Sarah P., Yu, Ly-Mee, Ellis, Stephanie, Hughes, Helen, Shaaban, Abeer, Fennelly-Barnwell, Jonathan, Lythgoe, Mark P., Cooper, Alison M., Maignen, Francois M., Buckland, Sean W., Kearns, Pamela R., Brown, Louise C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9702707/ https://www.ncbi.nlm.nih.gov/pubmed/36434156 http://dx.doi.org/10.1038/s41416-022-02051-7 |
Ejemplares similares
-
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
por: Blagden, Sarah P., et al.
Publicado: (2020) -
When technological innovations do not reach consensus: the case of tele-consultation of andrological patients
por: Verze, Paolo, et al.
Publicado: (2020) -
CostPlus and implications for generic imatinib
por: Jenei, Kristina, et al.
Publicado: (2022) -
A consensus-based transparency checklist
por: Aczel, Balazs, et al.
Publicado: (2019) -
Long COVID: aiming for a consensus
por: Munblit, Daniel, et al.
Publicado: (2022)